Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of kawasaki disease

Pediatric Infectious Disease Journal

Volumn 28, Issue 6, 2009, Pages 498-502

  Kobayashi, Tohru ^a   Inoue, Yoshinari ^a   Otani, Tetsuya ^b   Morikawa, Akihiro ^a   Kobayashi, Tomio ^c   Takeuchi, Kazuo ^d   Saji, Tsutomu ^e   Sonobe, Tomoyoshi ^f   Ogawa, Shunichi ^g   Miura, Masaru ^h   Arakawa, Hirokazu ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^c Gunma Children's Medical Center   (Japan)

^d SAITAMA UNIVERSITY   (Japan)

^e TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^g NIPPON MEDICAL SCHOOL   (Japan)

^h TOKYO METROPOLITAN CHILDREN'S MEDICAL CENTER   (Japan)

Author keywords

Coronary artery abnormalities; Intravenous immunoglobulin; Prednisolone; Risk stratification; Treatment failure

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; IMMUNOGLOBULIN; PREDNISOLONE;

ARTICLE; CHILD; CORONARY ARTERY ANEURYSM; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG INDICATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 67649534794     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181950b64     Document Type: Article

References (33)

1. Burns JC, Glode MP. Kawasaki syndrome. Lancet. 2004;364:533-544.
2. Suzuki A, Kamiya T, Kuwahara N, et al. Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr Cardiol. 1986;7:3-9.
3. Newburger JW, Takahashi M, Beiser AS, et al. Single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633-1639.
4. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics. 1979;63:175-179.
5. Shinohara M, Sone K, Tomomasa T, et al. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr. 1999;135:411-413.
6. Jibiki T, Terai M, Kurosaki T, et al. Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease. Eur J Pediatr. 2004;163:229-233.
7. Wooditch AC, Aronoff SC. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children. Pediatrics. 2005;116:989 -995.
8. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr. 2006;149:336-341.
9. Miura M, Ohki H, Yoshiba S, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child. 2005;90: 1096-1097.
10. Takahashi K, Oharaseki T, Wakayama M, et al. Pathological study of ruptured coronary artery aneurysms of Kawasaki disease (KD). In: Abstracts from the 2nd World Congress of Pediatric Cardiology and Cardiac Surgery; May 11-15, 1997; Honolulu, HI. Abstract 202.
11. Shulman ST. Is there a role for corticosteroids in Kawasaki disease? J Pediatr. 2003;142:601-603.
12. Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J. 1998;17:1144-1148.
13. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113:2606-2612.
14. Ayusawa M, Sonobe T, Uemura S, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int. 2005;47:232- 234.
15. Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn. 1991;33:805-810.
16. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110:2747-2771.
17. Rowley AH, Eckerley CA, Jack HM, et al. IgA plasma cells in vascular tissue of patients with Kawasaki disease. J Immunol. 1997;159:5946-5955.
18. Brown TJ, Crawford SE, Cornwall MI, et al. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis. 2001;184:940 -943.
19. Wright DA, Newburger JW, Baker A, et al. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr. 1996;128:146-149.
20. Dale RC, Saleem MA, Daw S, et al. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. J Pediatr. 2000;137: 723-726.
21. Hashino K, Ishii M, Iemura M, et al. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int. 2001;43:211-217.
22. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146:662-667.
23. Raman V, Kim J, Sharkey A, et al. Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy. Pediatr Infect Dis J. 2001;20: 635-637.
24. Imagawa T, Mori M, Miyamae T, et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr. 2004;163:263-264.
25. Wallace CA, French JW, Kahn SJ, et al. Initial intravenous gamma globulin treatment failure in Kawasaki disease. Pediatrics. 2000;105:e78.
26. Durongpisitkul K, Soongswang J, Laohaprasitiporn D, et al. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol. 2003;24:145- 148.
27. Furukawa S, Matsubara T, Yone K, et al. Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumor necrosis factor-alpha and interleukin 6 in serum. Eur J Pediatr. 1992;151:44-47.
28. Inoue Y, Kato M, Kobayashi T, et al. Increased circulating granulocyte colony-stimulating factor in acute Kawasaki disease. Pediatr Int. 1999;41: 330-333.
29. Okada Y, Shinohara M, Kobayashi T, et al. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr. 2003;143:363-367.
30. Lin CY, Lin CC, Hwang B, et al. Cytokines predict coronary aneurysm formation in Kawasaki disease patients. Eur J Pediatr. 1993;152:309-312.
31. Burns JC, Cayan DR, Tong G, et al. Seasonality and temporal clustering of Kawasaki syndrome. Epidemiology. 2005;16:220-225.
32. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007;356:663-675.
33. de Zorzi A, Colan SD, Gauvreau K, et al. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr. 1998; 133:254-258.